Skip to main content
Article thumbnail
Location of Repository

Prevention of atherosclerosis in patients living with HIV

By Ferruccio De Lorenzo, Marta Boffito, Sophie Collot-Teixeira, Brian Gazzard, John L McGregor, Kevin Shotliff and Han Xiao
Topics: Clinical Trial Protocol
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. 2: Joint British Societies’ guidelines on the prevention of cardiovascular disease in clinical practice.
  2. (2002). ACTG 5056: C-Reactive protein (CRP) levels and cardiovascular risk status for a cohort of HIV-1-infected persons Durably suppressed on an indinavir (IDV)-containing regimen.
  3. (2004). An emerging role for Kruppel-like factors in vascular biology. Trends Cardiovasc Med.
  4. (2005). Anti-infl ammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov.
  5. ARBITER: Arterial biology for the investigation of the treatment effects of reducing cholesterol: A randomized trial comparing the effects of aforvastatin and pravastatin on carotid intima media thickness.
  6. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors.
  7. (1997). Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk
  8. (1998). B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic fi ndings: a report of the Regression Growth Evaluation Statin Study (REGRESS).
  9. (2006). British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy
  10. (2006). C-reactive protein is a marker for human immunodefi ciency virus disease progression. Arch Intern Med.
  11. (2003). C-reactive protein is an independent predictor of mortality in women with HIV-1 infection. J Acquir Immune Defi c Syndr.
  12. C-reactive protein levels and outcomes after statin therapy.
  13. (2005). C-reactive protein levels in patients with HIV: a marker of cardiovascular risk or chronic infection?
  14. Cardiovascular risk and body-fat abnormalities in HIV-infected adults.
  15. Carotid artery intimal-media thickness distribution in general populations as evaluated by B-mode ultrasound.
  16. (2003). Carotid intima-media thickness in heavily pretreated HIV-infected patients. J Acquir Immune Defi c Syndr.
  17. (1999). Carotid intima-media thickness measurements: what defi nes an abnormality? A systematic review. Clin Invest Med.
  18. Class of antiretroviral drugs and the risk of myocardial infarction.
  19. Clinical value of C-reactive protein measurements in HIV-positive patients.
  20. Combination antiretroviral therapy and the risk of myocardial infarction.
  21. (1997). Common carotid intima-media thickness and risk of stroke and myocardial infarction: The Rotterdam Study. Circulation
  22. Comparison of intensive and low-dose atorvastatin therapy in the reduction of carotid intimal-medial thickness in patients with coronary heart disease.
  23. Comparison of the effi cacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
  24. Coronary heart disease in HIV-infected patients in the highly active antiretroviral treatment era.
  25. (2003). Coronary heart disease in HIVinfected individuals. J Acquir Immune Defi c Syndr.
  26. (2008). Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defi c Syndr.
  27. Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy.
  28. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.
  29. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
  30. (2004). Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther.
  31. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
  32. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
  33. (2006). Episodic CD4-guided use of ART is inferior to continuous therapy:
  34. (2002). Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med.
  35. (1994). for the Asymptomatic Carotid Artery Progression (ACAPS) Study Research Group. Effects of lovastatin on early carotid atherosclerosis and cardiovascular events. Circulation.
  36. for the Cardiovascular Health Study Collaborative Research Group. Carotid-artery intima media thickness as a risk factor for myocardial infarction and stroke in older adults.
  37. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.
  38. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages.
  39. (2006). Hospitalizations for CHD and MI among Northern California HIV+ and HIV− men: changes in practice and Framingham Risk Scores. Paper presented at:
  40. (1983). Incidence of myocardial infarctions in HIV-infected patients between
  41. (2003). Increasing Incidence of Cardiovascular Disease in HIV-infected Persons in Care.
  42. Inflammation and atherosclerosis: role of C-reactive protein in risk assessment.
  43. Inhibition of the mevalonate pathway: benefi ts beyond cholesterol reduction?
  44. Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
  45. Intimal plus medial thickness of the arterial wall: A direct measurement with ultrasound imaging.
  46. Isoprenoids as mediators of the biological effects of statins.
  47. KLF2 Is a novel transcriptional regulator of endothelial proinfl ammatory activation.
  48. (2005). Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function. Circ Res.
  49. (1995). Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation.
  50. (1999). Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Cirulcation.
  51. Metaanalysis of the studies assessing temporal changes in coronary plaque volume using intravascular ultrasound.
  52. (2002). Modulation of infl ammatory mediators and PPARgamma and NFkappa B expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res.
  53. Peroxisome proliferator-activated receptors as therapeutic targets in infl ammation.
  54. (2006). Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
  55. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors.
  56. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.
  57. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection.
  58. Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
  59. (1996). Reliability of longitudinal ultrasonic measurements of carotid intima-medial thickness.
  60. (1997). Reproducibility of ultrasonographic measurements of different carotid and femoral artery segments in healthy subjects and in patients with increase intima-media thickness. Clin Sci (Lond).
  61. (2004). Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation.
  62. (2004). Signaling to NF-kappa B. Genes Dev.
  63. State of the science conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS: executive summary.
  64. State of the Science Conference. Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS. Executivve summary.
  65. Statin induction of liver fatty acid-binding protein (L-FABP) gene expression is peroxisome proliferator-activated receptor-alpha-dependent.
  66. (2006). Statin therapy for native and peri-interventional coronary heart disease. Curr Mol Med.
  67. (2002). Statin therapy in acute coronary syndromes: mechanistic insight into clinical benefi t. Arterioscler Thromb Vasc Biol.
  68. (2006). Statin therapy-evidence beyond lipid lowering contributing to plaque stability. Curr Med Chem.
  69. Statins exert endothelial atheroprotective effects via the KLF2 transcription factor.
  70. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date metaanalysis.
  71. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation.
  72. (2003). T cell activation is associated with lower CD4+ T cell gains in human immunodefi ciency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis.
  73. (2000). T cell depletion in HIV-1 infection: how CD4+ T cells go out of stock. Nat Immunol.
  74. The KLEAN study of fosamprenavirritonavir versus lopinavir-ritonavir, each in combination with abacavirlamivudine, for initial treatment of HIV infection over 48 weeks: A randomised non-inferiority trial.
  75. The role of C-reactive protein activation of nuclear factor kappa-B in the pathogenesis of unstable angina.
  76. Thematic review series: patient-oriented research. Imaging atherosclerosis: state of the art.
  77. Use of human immunodefi ciency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction.
  78. with the Swiss HIV Cohort Study. Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.